Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics:

• Introduction (00:00)
• Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27)
• EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08)
• Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16)
• Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08)
• Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46)

CME information and select publications

Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics:

• Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)
• Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07)
• Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50)

CME information and select publications

Featuring an interview with Dr Jamie E Chaft, including the following topics:

• Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00)
• Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45)
• Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39)
• Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28)
• Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03)
• Importance of clinical trials in the adjuvant setting (33:02)
• Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41)
• Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34)
• Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01)

CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:

• Introduction (0:00)
• Overview of Antibody-Drug Conjugates (ADCs) (2:07)
• Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)
• Currently Available ADCs for Gynecologic Cancer Management (26:37)
• Currently Available ADCs for Lung Cancer Management (44:07)
• Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)
• Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)
• Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)

NCPD information and select publications

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics:

• Introduction (0:00)
• Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)
• Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)

CME information and select publications

Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics:

• Introduction (0:00)
• Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38)
• Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20)

CME information and select publications

Featuring an interview with Prof Martin Reck, including the following topics:

• Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)
• Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)
• Considerations with maintenance therapy for ES-SCLC (9:31)
• Considerations with immunotherapy for ES-SCLC (13:12)
• Curability of SCLC with systemic therapy (15:17)
• Data with chemoimmunotherapy for patients with poor performance status (25:55)
• Future developments in therapy for SCLC (30:11)
• Rapid fire: Small Cell 101 (35:45)

CME information and select publications

Dr Christine L Hann from the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the management of SCLC.

CME information and select publications